Medical Education

•  1973-1977 M.D., State University of New York at Buffalo Medical School, Buffalo, NY
•  1969-1973 B.S. Biology, Brandeis University, Waltham, MA

Residency and Fellowship

•  1983-1984 Visiting Fellow in Invasive Cardiology, Presbyterian Hospital, Columbia College of Physicians and Surgeons, New York, NY
•  1981-1983 Fellowship in Cardiology, Montefiore Hospital and Medical Center, Bronx, NY
•  1980-1981 National Institute of Health Research Fellowship in Cardiovascular Disease, Montefiore Hospital and Medical Center, Bronx, NY
•  1978-1980 Medical Resident, Montefiore Hospital and Medical Center, Bronx, NY
•  1977-1978 Medical Intern, Montefiore Hospital and Medical Center, Bronx, NY

Licensure and Board Certification

New York Licensure
New Jersey Licensure

•  2009 Recertified, Interventional Cardiology Subspecialty Board
•  1984 Certified, Cardiovascular Subspecialty Board, Fellow of the American College of Cardiology
•  1980 Diplomate, American Board of Internal Medicine

Hospital Appointments

•  2011-present Medical Director of the Cardiovascular Institute Medical Director of Clinical Innovation and Quality Good Samaritan Hospital, Suffern, NY
•  2011-present Chief of Metropolitan Cardiology Consultants , a member of Bon Secours Medical Group Bon Secours Charity Health System, Suffern, NY
•  2007-Present Director, Cardiac Catheterization Laboratory and Director of Cardiology Clinical Trials, Good Samaritan Hospital, Suffern, NY
•  2007-present Director, Cardiology St. Anthony Community Hospital, Warwick, NY
•  2007-present Director, Nuclear Cardiology Bon Secours Community Hospital, Port Jervis, NY 
•  2003-2007 Director, Cardiac Catheterization Laboratory, The Valley Hospital, Ridgewood, NJ
•  1998-2004, Director of Interventional Cardiology, The Valley Hospital, Ridgewood, New Jersey
•  1994-2002 Attending Physician, Department of Medicine, St. Luke's-Roosevelt Hospital Center, New York, NY
•  1989-present Attending Physician, Department of Medicine, The Valley Hospital, Ridgewood, NJ
•  1988-present Cardiology Consultant, St. Anthony Community Hospital, Warwick, NY
•  1987-present Attending Physician, Department of Medicine, Nyack Hospital, Nyack, NY
•  1986-1991 Director, Cardiac Catheterization Laboratory, Good Samaritan Hospital, Suffern, NY
•  1998-2007 Director of Interventional Cardiology, The Valley Hospital, Ridgewood, NJ

Professional Memberships

•  Fellow of American College of Cardiology
•  New York Heart Association
•  Society for Cardiac Angiography and Interventions
•  New Jersey Chapter, American College of Cardiology
•  New York Chapter, American College of Cardiology
•  American Heart Association
•  Program Director Annual Cardiology Conference of The Orange, Rockland, and Sullivan County Chapters of The New York
•  State Cardiology Society and American Heart Association
•  American Society of Internal Medicine
•  The New York Cardiological Society
•  The American Medical Association
•  The Rockland County Medical Association
•  The Orange County Medical Association

 Awards & Honors

•  Expert Reviewer for Interventional Cardiology Boards
•  America's Top Physician-Interventional Cardiology, Consumers Research Council of America
•  Key Note Speaker – Go Red for Women – American Heart Association
•  Honorary Speaker:

  Merck & Co.

  Parke-Davis

  Guidant Corporation

  Genentech

  Bristol-Myers Squibb

  Abbott Pharmaceutical

  Novartis

  Pharmaceutical, King Pharmaceutical, Pfizer

• New York State Regents Scholarship, 1969
• National Merit Letter of Commendation, 1969

Clinical Investigations

•  Principal Investigator: XIENCE V: Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study: 06-374
  Sponsor: Abbott Vascular
  Duration: September 2008-Present
•  Principal Investigator: TRACER: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with Acute Coronary Syndrome: Thrombin- Receptor-Antagonist-for-Clinical-Events-Reduction in Acute Coronary Syndrome.
  Sponsor: Schering-Plough
  Duration: August 2008-Present.
•  Principal Investigator: COGENTUS: A Randomized, Double-Blind, Double- Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symptomatic Ulcer Disease.
  Sponsor: Cogentus Pharmaceuticals, Inc.
  Duration: August 2008-December 2008
•  Principal Investigator: PLATO: A Study of PLATelet inhibition and patient Outcomes: A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST and ST Elevation Acute Coronary Syndromes (ACS)

  Sponsor: AstraZenica
  Duration: December 2006–April 2009

•  Principal Investigator: APX-PHP-05-001: A Phase II, Multi-Center, Randomized, Placebo Controlled Proof Of-Concept Study of PHP when Administered by Continuous Infusion to Patients with Cardiogenic Shock.

  Sponsor: Apex Bioscience, Inc.
  Duration: November 2006-December 2008

•  Principal Investigator: SPIRIT IV: Clinical Evaluation of the XienceTMV Everolimus Coronary Stent System in the treatment of Subjects with de Novo Coronary Artery Lesions.

  Sponsor: Abbott/Guidant
  Duration: September 2006-Present

•  Principal Investigator: FREEDOM TRIAL: Future Revascularization evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel disease

  Sponsor: The Cardiovascular Research Foundation
  Duration: May 12, 2005-Present

•  Principal Investigator: HORIZONS AMI TRIAL: Harmonizing Outcomes with Revascularization and Stents

  Sponsor: The Cardiovascular Research Foundation
  Duration: May 12, 2005-Present

•  Principal Investigator: SPIRIT III: A Clinical Evaluation of XIENCE™ V Everolimus Eluting Coronary Stent System in the Treatment of Subjects with de novo Native Coronary Artery Lesions

  Sponsor: Guidant Corporation
  Duration: December 9, 2004-Present

•  Principal Investigator: STRADIVARIUS: A randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg od. For Inhibition of Atherosclerosis Progression Assessed by IVUS, in Overweight Patients with Clustering Risk Factors

  Sponsor: Sanofi-Synthelabo
  Duration: December 9, 2004-September 2008

•  Principal Investigator: D.E.S. COVER REGISTRY

  Sponsor: Cordis Corporation
  Duration: June 8, 2004-June 2005 

•  Principal Investigator: TAXUS IV-SR: Treatment of DeNovo coronary disease using single paclitaxel-eluting stents.

  Sponsor: Boston Scientific-Scimed
  Duration: April 2, 2003-September 2008

•  Principal Investigator: TAXUS IV: A prospective, randomized trial evaluating Taxus Paclitaxel – Eluting Coronary Stent in De Novo Coronary Lesion and In-Stent Restenosis.

  Sponsor: Boston Scientific-Scimed
  Duration: October 26, 2001-September 2008 

•  Principal Investigator: VOLCANO: Evaluation of the Safety and Effectiveness of the Volcano Revolution 45MHz Rotational IVUS Imaging Catheter and IVG3 SpinVision System in Subjects with Coronary Artery Disease.

  Sponsor: Volcano, Corp.
  Duration: January 2006-March 2006

•  Principal Investigator: THE ACUITY TRIAL: A randomized comparison of Angiomax® (bivalirudin) versus heparin (enoxaparin or unfractioned heparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation.

  Sponsor: The Medicines Company
  Duration: December 11, 2003-July 2006

•  Principal Investigator: A5091005: Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally. Once Daily (QD) for 24 Months, Compared with Atoravastatin Alone, in Subjects with Angiographically documented Coronary Heart Disease

  Sponsor: Pfizer
  Duration: October 9, 2003-December 2006

•  Principal Investigator: PERISCOPE: A double-blind randomized comparator-controlled study in subjects with Type II diabetus mellitus comparing the effects of Pioglitazone HVL vs Glimepiride on the rate of progression of atherosclerotic disease as measured by intravascular ultrasound

  Sponsor: Takeda Pharmacutical North America, Inc.
  Duration: July 2003-5/12/2005

•  Principal Investigator: DUET REGISTRY: Closure Device Registry

  Sponsor: Vascular Solution
  Duration: January 2001 – 2002

•  Principal Investigator: REGISTRY: Saphenous Vein Graft Angioplasty Free of Emboli Randomized Study

  Sponsor: Percusurge, Inc.
  Duration: 12/2000 - 2002

•  Principal Investigator: HEPACOAT REGISTRY: An open evaluation comparing stent thrombosis rate of the BX velocityTM Heparin-coated (HEPACOAT) stent to the BX velocity TM stent.

  Sponsor: Cordis
  Duration: October 4, 2000 – 2002

•  Principal Investigator: SENIOR PAMI: Acute MI in ER and Cath Lab

  Sponsor: National Institute of Health
  Duration: 9/1/00-2003

•  Principal Investigator: ENTIRE TRIAL: Acute MI in ER and Cath Lab

  Sponsor: Aventis
  Duration: 9/1/00-2002

•  Principal Investigator: REGISTRY: Left Main IVUS Registry

  Sponsor: Scripps Clinic
  Duration: May 2000 – 2002

• Principal Investigator: OAT STUDY: Occluded Artery Trial

  Sponsor: National Institute of Health
  Duration: 1/13/00 – 12/15/2003

•  Principal Investigator: TARGET TRIAL: Tirofiban and Reopro Give Similar Efficacy Outcomes Trial

  Sponsor: Merck & Co.
  Duration: 12/9/99 –August 2000

•  Principal Investigator: SUPPORT TRIAL: Stent Acute Performance: Comparison of NIR Stent vs Other Coronary Stents

  Sponsor: Boston Scientific Scimed
  Duration: 11/11/99 – 2002

•  Principal Investigator: SAFER TRIAL: Saphenous Vein Graft Angioplasty Free of Emboli Randomized Study

  Sponsor: Percusurge, Inc.
  Duration: 7/13/99 – August 2000

•  Sub-Investigator: ATLAS ACS TIMI 46 TRIAL: A randomized, Double-Blind, Placebo-Controlled, Multicenter, dose-Escalation and dose-confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in combination with Aspirin alone or with Aspirin and a Thienopyridine in Subjects with Acute Coronary Syndromes.

  Sponsor: Bayer Pharmaceuticals Corporation
  Duration: December 2006 – present

•  Sub-Investigator: PRECISION: A Randomized, Double Blind, Parallel Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoic Arthritis Patients With or at High Risk of Cardiovascular Disease Comparing Celecoxib with Naproxen and Ibuprofen

  Sponsor: Pfizer
  Duration: December 2006 – present

•  Sub-Investigator: RE-LY: Randomized Evaluation of Long Term anticoagulant Therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation; prospective, multi-centre, parallel-group, non-inferiority trial. (RE-LY Study) Protocol dated: September 12, 2005

  Sponsor: Boehringer Ingelheim Pharmaceuticals
  Duration: September 2006 – present

•  Sub-Investigator: TOPCAT: Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist.

  Sponsor: NHLBI, NIH/DHHS
  Duration: May 2006 - present

•  Sub-Investigator: IMPROVE-IT: A Multicenter, Double-blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High Risk Subjects Presenting with Acute Coronary Syndrome (Improved Reduction of Outcomes)

  Sponsor: Schrilling-Plough
  Duration: October 2005-Present

•  Sub-Investigator: ENDEAVOR IV: A Randomized, Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in the De Novo Native Coronary Artery Lesions

  Sponsor: Medtronic, Inc.
  Duration: May 12, 2005 - present

•  Sub-Investigator: TRITON/TIMI 38: A Comparison of CS-747 and Clopidogrel in Acute coronary Syndrome Subjects who are to undergo percutaneous coronary intervention/TIMI-38

  Sponsor: Eli Lilly and Company
  Duration: December 9, 2004-Present

•  Sub-Investigator: EVEREST TRIAL: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure.

  Sponsor: Otsuka Maryland, Inc.
  Duration: November 10, 2003 - June 2006

•  Sub-Investigator: PROXIMAL: Proximal Protection during Saphenous Vein Graft Intervention Using the Proxis Embolic Protection System: A Randomized, Prospective Multicenter, Clinical Trial.

  Sponsor: Velocimed, Inc.
  Duration: October 24, 2003 – February 2005

 Research Publications

•  Moses, J.W., Mehran, R., Nikolsky, E, Lasala, J.M., Corey, W., Albin, G., Hirsch, C., Leon, M.B., Russell, M.E., Ellis, S.G., Stone, G.W.: “Outcomes With the Pacliltaxel-Eluting Stent in Patients With Acute Coronary Syndromes” Journal of the American College of Cardiology, Vol. 45, No. 8, 2005, April 19, 2005.
•  Scheuer, J., Hirsch, C., Cappasso, J., Schaible, T.R.: “Physiological Cardiac Hypertrophy Corrects Contractile Protein Abnormalities Associated With Pathological Hypertrophy in Rats” Journal of Clinical Investigation, December 1982

 Abstracts

•  Strain, Janet E., Grose, Richard M., Hirsch, Cary L., Kramer, David C., Sangki, Cho, Factor, Stephen M., “Atypical Presentation of Myocarditis, Circulation, Vol. 68, Supp. III, October, 1983